Valneva SE shares rise 5.42% intraday after announcing an exclusive vaccine marketing and distribution agreement with CSL Seqirus.

Valneva SE rose 5.42% in intraday trading, driven by the announcement of an exclusive agreement with CSL Seqirus for the marketing and distribution of Valneva's three proprietary vaccines in Germany. The agreement includes the commercialization of Valneva's single-dose chikungunya vaccine IXCHIQ from July 2025, and its Japanese Encephalitis vaccine IXIARO and cholera/ETEC1 vaccine DUKORAL from January 2026. This new partnership replaces the previous agreement with Bavarian Nordic and is set to last for three years, with minimum annual purchasing quantities and standard termination clauses.